FDA Inspection 1275961 — Evonik Rexim S.A.S.
The FDA completed an inspection of Evonik Rexim S.A.S. on March 28, 2024 in Ham. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- March 28, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Ham (France)
Additional Details
Mutual Recognition Agreement (MRA)